IOVA - Iovance Biotherapeutics, Inc.
About Iovance Biotherapeutics, Inc. (https://www.iovance.com)
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Frederick G. Vogt | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director | 1974 | $1,128,800 USD |
| Raj K. Puri | Chief Regulatory Officer | 1956 | $867,158 USD |
| Daniel G. Kirby | Chief Commercial Officer | 1972 | $804,031 USD |
| Friedrich Graf Finckenstein | Chief Medical Officer | 1967 | $764,634 USD |
| Igor Bilinsky | Chief Operating Officer | 1973 | $738,374 USD |
| Corleen Roche | Chief Financial Officer | 1966 | $494,150 USD |
| Elma S. Hawkins | Advisor to the Board | 1957 | $465,395 USD |
| Brian Shew | Senior Vice President & Head of Digital and Information Technology | – | – |
| Howard Johnson | Chief Business Officer | 1960 | – |
| Kevin Smyth | Executive Vice President of Quality | – | – |
| Marc R. Theoret | Senior Vice President of Regulatory Strategy | – | – |
| Matthew W. Rosinack | Principal Accounting Officer | 1972 | – |
| Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | – | – |
| Tracy Winton | Executive Vice President of Human Resources | – | – |